Tumors glow pink under blue light.
UW Medicine urologists with Seattle Cancer Care Alliance (SCCA) were the first in Washington state to offer an innovative bladder cancer tumor detection method known as blue-light cystoscopy.
“Seventy percent of bladder cancer patients have non-muscle-invasive disease.That’s the population who can benefit,” said Jonathan Wright, M.D., a professor of urology at the University of Washington School of Medicine in a press release.
This technology can be helpful especially since the pandemic has delayed doctor visits.“We’ve definitely seen patients afraid to come in. And that’s led to delay in diagnosis, further advanced cancers and more difficulty in treating them,” said Wright in the press release.
The SCCA is listed on the National Comprehensive Cancer Network as one of the 31 leading cancer centers in the United States.
Non-muscle-invasive bladder cancer is a type of urothelial carcinoma. According to the American Urological Association, enhanced cystoscopy — which includes blue-light cystoscopy — should be offered to patients with non-muscle-invasive bladder cancer at the time of transurethral resection of bladder tumor, if available, to increase the chances of detection and decrease cancer recurrence.
Photocure’s Cysview (hexaminolevulinate HCl) is an FDA approved product that makes non-muscle invasive tumors glow bright pink under blue light during cystoscopy, making the cancer more visible.Approximately an hour before the cystoscopy, the patient has approximately two ounces of Cysview solution placed into the bladder via a catheter.The urologist examines the bladder with white light first to determine whether there is anything suspicious. Next, the urologist switches to blue light, which causes the tumors to glow bright pink.
Evidence shows that blue light cystoscopy with Cysview is safe and effective.The most common adverse effects include bladder spasm, painful urination, blood in the urine, bladder pain, pain during the procedure, urinary infection, and headache. Urologists who perform the procedure with Cysview receive training on the imaging solution and technology.
Meet the Board: Otis Brawley Talks Health, Racial Disparities, Cancer Screenings and More
September 30th 2020This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Listen
3 Upcoming Urothelial Cancer Conferences
August 12th 2021At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Read More
Updated SITC Immunotherapy Guidelines for Urothelial Cancer
August 3rd 2021The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).
Read More
Integrating Advanced Practice Providers into Oncology Settings for Managing Urothelial Cancer
July 6th 2021According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.
Read More